Journal
DRUG DISCOVERY TODAY
Volume 25, Issue 2, Pages 456-465Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.11.010
Keywords
-
Categories
Funding
- NIH [R03DA044877]
- Campbell Foundation (Florida, USA)
- SOP-Office of Science
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center (TTUHSC), TX, USA
- Department of Anesthesiology, College of Medicine, University of Nebraska Medical Center (UNMC), Omaha, NE, USA
Ask authors/readers for more resources
The paradigm of central nervous system (CNS) drug discovery has mostly relied on traditional approaches of rodent models or cell-based in vitro models. Owing to the issues of species differences between humans and rodents, it is difficult to correlate the robustness of data for neurodevelopmental studies. With advances in the stem-cell field, 3D CNS organoids have been developed and explored owing to their resemblance to the human brain architecture and functions. Further, CNS organoids provide a unique opportunity to mimic the human brain physiology and serve as a modeling tool to study the normal versus pathological brain or the elucidation of mechanisms of neurological disorders. Here, we discuss the recent application of a CNS organoid explored for neurodevelopment disease or a screening tool for CNS drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available